Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
31 HKD | +1.81% | +1.84% | -22.12% |
Apr. 29 | China, HK stocks rise, led by property shares | RE |
Apr. 11 | China stocks rise as commodities shine; Hong Kong snaps winning streak | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.7 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.12% | 12.04B | B | ||
-24.76% | 6.52B | B | ||
+15.41% | 6.44B | C | ||
-10.11% | 6.15B | C+ | ||
-2.48% | 4.63B | D- | ||
+60.00% | 4.62B | C | ||
-6.67% | 3.93B | B | ||
-10.60% | 3.49B | C- | ||
-6.53% | 3.05B | C- | ||
-8.74% | 2.69B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6618 Stock
- Ratings JD Health International Inc.